Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1997 Jun;52(6):507–512. doi: 10.1136/thx.52.6.507

Malignant mesothelioma in south east England: clinicopathological experience of 272 cases [published erratum appears in Thorax 1997 Nov;52(11):1018]

D H Yates, B Corrin, P N Stidolph, K Browne
PMCID: PMC1758573  PMID: 9227715

Abstract

BACKGROUND: Malignant mesothelioma is a rare pleural tumour associated with asbestos exposure. The proportion of malignant mesothelioma unrelated to asbestos exposure, and any differentiating features between exposed and unexposed cases, are not well described. This study describes occupational, clinical, and pathological features in a large cohort of cases of malignant mesothelioma from south east England. METHODS: All 272 cases from this region were studied, either in life or after death when necropsy examination suggested malignant mesothelioma. Detailed information was gathered regarding the occupational history, clinical course, and mode of death. Necropsies were performed in 98% of cases. Lung tissue was examined histologically to confirm the diagnosis, subtype of tumour, presence or absence of asbestosis and asbestos bodies. RESULTS: Exposure to asbestos was documented in 87% of cases, while in the remainder, no asbestos exposure was found nor were asbestos bodies seen; 94.5% were pleural, 5.1% peritoneal, and 0.4% pericardial. Right sided tumours were more common than left sided tumours (ratio 1.6:1). Patients usually presented with breathlessness and chest pain, but 33% presented with pleural effusion in the absence of chest pain. The mean (SD) time from first exposure to asbestos to symptoms was 40 (12) years with a median (interquartile range (IQR) survival of 14 (12.5) months. The median (IQR) survival time in sarcomatous, epithelial, and mixed cell type malignant mesothelioma was 9.4 (10) months, 12.5 (18) months, and 11 (14) months, respectively, and was significantly greater in cases detected by chance. Clinical features were similar in asbestos related and non-asbestos related malignant mesothelioma. CONCLUSIONS: In south east England most cases of malignant mesothelioma are associated with asbestos exposure. Clinical features do not differentiate between asbestos related and non- asbestos related disease. 




Full Text

The Full Text of this article is available as a PDF (131.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boutin C., Rey F., Gouvernet J. Le mésothéliome malin: facteurs pronostiques dans une série de 125 patients étudiés de 1973 à 1987. Bull Acad Natl Med. 1992 Jan;176(1):105–117. [PubMed] [Google Scholar]
  2. Dorward A. J., Stack B. H. Diffuse malignant pleural mesothelioma in Glasgow. Br J Dis Chest. 1981 Oct;75(4):397–402. doi: 10.1016/0007-0971(81)90027-9. [DOI] [PubMed] [Google Scholar]
  3. Elmes P. C., Simpson J. C. The clinical aspects of mesothelioma. Q J Med. 1976 Jul;45(179):427–449. [PubMed] [Google Scholar]
  4. Hirsch A., Brochard P., De Cremoux H., Erkan L., Sebastien P., Di Menza L., Bignon J. Features of asbestos-exposed and unexposed mesothelioma. Am J Ind Med. 1982;3(4):413–422. doi: 10.1002/ajim.4700030407. [DOI] [PubMed] [Google Scholar]
  5. Lanphear B. P., Buncher C. R. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992 Jul;34(7):718–721. [PubMed] [Google Scholar]
  6. Law M. R., Ward F. G., Hodson M. E., Heard B. E. Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure. Thorax. 1983 Oct;38(10):744–746. doi: 10.1136/thx.38.10.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. McDonald A. D., Magner D., Eyssen G. Primary malignant mesothelial tumors in Canada, 1960-1968. A pathologic review by the Mesothelioma Panel of the Canadian Tumor Reference Centre. Cancer. 1973 Apr;31(4):869–876. doi: 10.1002/1097-0142(197304)31:4<869::aid-cncr2820310416>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  8. Peto J., Hodgson J. T., Matthews F. E., Jones J. R. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995 Mar 4;345(8949):535–539. doi: 10.1016/s0140-6736(95)90462-x. [DOI] [PubMed] [Google Scholar]
  9. Ribak J., Lilis R., Suzuki Y., Penner L., Selikoff I. J. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Br J Ind Med. 1988 Mar;45(3):182–187. doi: 10.1136/oem.45.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Roberts G. H. Diffuse pleural mesothelioma. A clinical and pathological study. Br J Dis Chest. 1970 Oct;64(4):201–211. doi: 10.1016/s0007-0971(70)80016-x. [DOI] [PubMed] [Google Scholar]
  11. Spirtas R., Heineman E. F., Bernstein L., Beebe G. W., Keehn R. J., Stark A., Harlow B. L., Benichou J. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994 Dec;51(12):804–811. doi: 10.1136/oem.51.12.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Whitwell F., Rawcliffe R. M. Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax. 1971 Jan;26(1):6–22. doi: 10.1136/thx.26.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wright W. E., Sherwin R. P., Dickson E. A., Bernstein L., Fromm J. B., Henderson B. E. Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology. Br J Ind Med. 1984 Feb;41(1):39–45. doi: 10.1136/oem.41.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES